Literature DB >> 1940919

Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats.

D Ben-Shachar1, M B Youdim.   

Abstract

Elevated iron concentrations in the substantia nigra (SN) pars compacta have been implicated in the development of idiopathic Parkinson's disease. Because, as a transitional metal, iron promotes free radical formation, the role of iron in the degeneration of the nigrostriatal dopamine neurons in Parkinson's disease has received much attention. This study further investigates the cytotoxic effects of iron in the SN. Various concentrations of FeCl3 (1, 5, and 50 micrograms of Fe3+ in 5 microliters) were unilaterally injected into the SN of adult rats. The two lower doses of iron had no effect on striatal dopamine levels or on the behavioral responses of the rats. However, injection of 50 micrograms of Fe3+ resulted in a substantial selective decrease of striatal dopamine (95%), 3,4-dihydroxyphenylacetic acid (82%), and homovanillic acid (45%), without any change in norepinephrine concentration. Dopamine-related behavioral responses, such as spontaneous movements in a novel space and rearing, were significantly impaired, whereas amphetamine administration induced ipsilateral rotation in the iron-treated rats. The present study indicates that the nigrostriatal dopamine neurons are susceptible to the presence of ionic iron and thus supports the assumption that iron initiates dopaminergic neurodegeneration in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1940919     DOI: 10.1111/j.1471-4159.1991.tb06432.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  33 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 2.  Iron and mechanisms of emotional behavior.

Authors:  Jonghan Kim; Marianne Wessling-Resnick
Journal:  J Nutr Biochem       Date:  2014-08-02       Impact factor: 6.048

Review 3.  Genetics of iron regulation and the possible role of iron in Parkinson's disease.

Authors:  Shannon L Rhodes; Beate Ritz
Journal:  Neurobiol Dis       Date:  2008-07-11       Impact factor: 5.996

4.  Pooled analysis of iron-related genes in Parkinson's disease: association with transferrin.

Authors:  Shannon L Rhodes; Daniel D Buchanan; Ismaïl Ahmed; Kent D Taylor; Marie-Anne Loriot; Janet S Sinsheimer; Jeff M Bronstein; Alexis Elbaz; George D Mellick; Jerome I Rotter; Beate Ritz
Journal:  Neurobiol Dis       Date:  2013-10-08       Impact factor: 5.996

Review 5.  Mitochondrial dysfunction in neurodegeneration.

Authors:  J M Cooper; A H Schapira
Journal:  J Bioenerg Biomembr       Date:  1997-04       Impact factor: 2.945

Review 6.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 7.  Iron metabolism and its detection through MRI in parkinsonian disorders: a systematic review.

Authors:  Sara Pietracupa; Antonio Martin-Bastida; Paola Piccini
Journal:  Neurol Sci       Date:  2017-09-02       Impact factor: 3.307

8.  Brain iron concentrations in regions of interest and relation with serum iron levels in Parkinson disease.

Authors:  Paola Costa-Mallen; Christopher Gatenby; Sally Friend; Kenneth R Maravilla; Shu-Ching Hu; Kevin C Cain; Pinky Agarwal; Yoshimi Anzai
Journal:  J Neurol Sci       Date:  2017-04-23       Impact factor: 3.181

9.  Low brain iron effects and reversibility on striatal dopamine dynamics.

Authors:  Erica L Unger; Laura E Bianco; Byron C Jones; Richard P Allen; Christopher J Earley
Journal:  Exp Neurol       Date:  2014-07-03       Impact factor: 5.330

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.